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Abstract
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characterize PCOS, and are correlated to increased BMD. PCOS is also associated with symptoms and
comorbid conditions, like chronic vitamin D deficiency, menstrual dysfunction, and hypothyroidism, which
are all correlated with decreased BMD. Existing research on this topic reports conflicting results; some
studies show a significant correlation between PCOS and increased BMD, while others suggest that no
significant correlation exists. These previous studies focused on load-bearing areas of the skeleton,
which may obscure results because of a strong correlation between PCOS and high body mass indices
(BMI). The current study uses full-body, dual-energy X-ray absorptiometry (DEXA) scans to compare the
cranial bone and total BMD of 18 to 45 year old, non-smoking subjects with PCOS with healthy, age- and
BMl-matched controls. The present study found that cranial bone BMD is a region of the skeleton that is
not affected by mechanical loading, and is a useful metric for assessing systemic changes to BMD.
Secondly, a significant, positive correlation between age and cranial BMD was observed in the PCOS
sample that was not observed in the control sample. Finally, no correlation was observed between cranial
BMD and total BMD in the PCOS sample, but was observed in the control sample. These results suggest
that PCOS has a systemic effect on BMD independent of weight.
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Abstract
The purpose of this pilot study is to determine the systemic effects of Polycystic
Ovary Syndrome (PCOS) on bone mineral density (BMD). Excessive male sex
honnones, excessive insulin levels, and weight gain characterize PCOS, and are
correlated to increased BMD. PCOS is also associated with symptoms and comorbid
conditions, like chronic vitamin D deficiency, menstrual dysfunction, and
hypothyroidism, which are all correlated with decreased BMD. Existing research on this
topic reports conflicting results; some studies show a significant correlation between
PCOS and increased BMD, while others suggest that no significant correlation exists.
These previous studies focused on load-bearing areas of the skeleton, which may obscure
results because of a strong correlation between PCOS and high body mass indices (BMI).
The current study uses full-body, dual-energy X-ray absorptiometry (DEXA) scans to
compare the cranial bone and total BMD of 18 to 45 year old, non-smoking subjects with
PCOS with healthy, age- and BMl-matched controls. The present study found that cranial
bone BMD is a region of the skeleton that is not affected by mechanical loading, and is a
useful metric for assessing systemic changes to BMD. Secondly, a significant, positive
correlation between age and cranial BMD was observed in the PCOS sample that was not
observed in the control sample. Finally, no correlation was observed between cranial
BMD and total BMD in the PCOS sample, but was observed in the control sample. These
results suggest that PCOS has a systemic effect on BMD independent of weight.
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Introduction
Polycystic Ovary Syndrome (PCOS) affects 6.5 to 8.0% of women, making it the
most common endocrine disorder in women. 1 The syndrome is characterized by a variety
of common symptoms, like excessive male sex hormones, insulin resistance, menstrual
and ovulatory dysfunction, and cystic ovaries. 1 Other common symptoms include
imbalanced female sex hormones, infertility, hirsutism (unwanted hair growth on the
face, chest, and back), increased lean muscle mass, and high body mass indices
(BMI). 1 .2.3 In addition to the symptoms of PCOS, patients with the syndrome often suffer
from comorbid conditions such as hypothyroidism, temporomandibular joint disorder,
systemic inflammation and osteoarthritis, and nutrient deficiencies such as vitamin D
deficiency.4•5•6•7•8 Increased risk of metabolic syndrome, certain reproductive cancers,
high cholesterol, non-alcoholic fatty liver disease, and other complications have been
observed in people with PCOS.9• 10•1 1 Together, the symptomology, comorbidities, and
complications associated with PCOS make this syndrome a serious public health concern.
Despite this, little is known about what causes PCOS, and scientific knowledge about the
immediate and long-term consequences of the syndrome is incomplete.
One area of knowledge that is particularly confounding is whether PCOS has a
positive, negative, or no effect on bone mineral density (BMD). Much of the research
reports a statistically significant positive correlation between PCOS and increased BMD
(e.g. patients with the disease have higher BMD than healthy controls).3• 12•13• 14 Multiple
theories exist about what aspect of PCOS may cause the observed gains in BMD. One
hypothesis is that the excessive endogenous male sex hormones characteristic of PCOS
cause patients with the syndrome to have bone growth similar to that of males because of

6

the important role these honnones play in bone growth and development. 15 Another
theory is that excessive male sex honnones make it easier for PCOS patients to develop
lean muscle mass, which is positively correlated with high BMD.2• 13• 16• 17 Conversely,
other research suggests that the BMD of individuals with PCOS is not significantly
greater than that of healthy individuals.2• 13• 18 It is possible that symptoms like menstrual
dysfunction, hypothyroidism, and chronic vitamin D deficiency may counteract any
effect of excessive male sex honnones on bone growth and lead to low BMD.
The existing research about the effect of PCOS on BMD focuses on load-bearing
areas of the skeleton, like the head of the femur and the lumbar spine. However,
mechanical loading increases BMD locally, which potentially masks the systemic effects
of PCOS on BMD. It is important to note that a study by Douchi and colleagues on the
effect of PCOS on BMD uses the left arm, which these researchers argue is a non-load
bearing area of the skeleton. 16 While this may be true in people with healthy BMI, it is
not the case in people who are overweight or obese. This is because individuals who are
overweight or obese require the use of their arms to support their weight during sit-to
stand movement. In a study by Hills and colleagues (2002), 70% of obese children
required assistance when asked to stand without using their upper bodies. Other studies
show that morbidly obese adults also require the use of their upper limbs to stand and to
avoid injury during activity. 1 9•20•2 1 Patients with PCOS are more often overweight or
obese than lean, so the radius should not be assumed to be a non-load-bearing region of
the skeleton when studying the effect of PCOS on BMD. Load-bearing areas of the
skeleton become denser as weight increases, and because patients with PCOS commonly
have high BMI compared to healthy individuals, these patients will most likely have
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higher BMD localized to load-bearing areas of the skeleton. Studies that focus on load
bearing areas will have a difficult time differentiating whether a patient's BMD is high
because of increased weight or because of some other aspect of PCOS. Furthermore,
studies that focus on load-bearing areas cannot discriminate whether the effect of PCOS
on BMD is localized to these regions of the skeleton, or if the effect is systemic.
These gaps in the existing research inspired this undergraduate Honors thesis. In
the current study, the goal is to determine whether PCOS has a statistically significant
effect on BMD, and if so, whether that effect is systemic. To answer these questions, the
investigators use total body dual-energy x-ray absorptiometry (DEXA) scans to gather
data about body composition and BMD. This data can be used to compare total body,
head, and vault BMD (head excluding teeth) to determine whether there is a significant
difference in BMD of these regions between test and control group members. This
research also allows the investigators to confirm whether vault BMD is affected by load
bearing or not. If cranial vault BMD is not affected by load-bearing, but does exhibit a
significant difference in BMD when comparing the test and control group subjects, it
would suggest that the effect of PCOS on the skeleton is systemic rather than localized to
load-bearing areas of the skeleton.
While the study presented in this paper is a pilot study with a small sample size, it
is an important step toward a better understanding of the effects ofPCOS on the body. A
richer understanding of the effect of PCOS on BMD can help clinicians choose treatment
options for patients that are directed toward improving BMD and preventing BMD loss
leading to osteoporosis (i.e., increased fracture risk). Given that PCOS is a public health
concern, this research will benefit patients with PCOS, and society as a whole, by
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increasing the general knowledge about this remarkably common disease. With each new
piece of information about PCOS, clinicians can develop better treatment plans. Patients
with PCOS, in turn, can expect better clinical outcomes, improving their health and well
being.
This paper begins with a comprehensive literature review in which PCOS is more
clearly defined and the diagnostic criteria, various symptoms, comorbid conditions, and
complications of the syndrome are explained.

Background
Defining PCOS
PCOS is a cluster of consistently comorbid symptoms disrupting the endocrine
systems of affected patients. PCOS is characterized by hyperandrogenemia {excessive
male sex hormones). There exist other hyperandrogenic conditions {characterized by
excessive male sex hormones), like Cushing's Disease. 1 Additional symptoms are noted
and the occurrence of these symptoms tends to be highly varied, leading researchers to
regard PCOS as a mostly heterogeneous condition.1 Aside from hyperandrogenemia, the
most common symptoms are oligomenorrhea {infrequent menstruation) or amenorrhea
{absent menstruation) and ovarian cysts. These two symptoms are included in the
diagnostic criteria of the syndrome. 1 Patients with PCOS may also present with symptoms
such as: Insulin Resistance {IR) or hyperinsulinemia, hirsutism {excessive hair growth,
particularly on the face, chest, and back), weight gain and obesity, infertility, acne,
alopecia (hair loss, particularly on the scalp), vitamin D deficiency, osteoarthritis, and
temporomandibular joint disorders. 1•6•7•8
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Additional, long-term effects of PCOS exist. Patients with PCOS are at greater
risk of developing metabolic syndrome, which are obesity related conditions that increase
a person's risk of diabetes, cardiovascular disease, and stroke.9 PCOS increases the risk
of reproductive cancers, like endometrial cancer, due to menstrual and ovulatory
dysfunction.9• 10 Patients with PCOS are also at increased risk of developing other chronic
diseases as they age, including non-alcoholic fatty liver disease, dyslipidemia, and
hypertension.9• 1 1 However, many of these long-term risks can be mitigated or prevented
with appropriate lifestyle changes and treatment.9

Diagnosing PCOS
The high variability of PCOS has made it difficult for clinicians and researchers
to determine a singular diagnostic criterion. According to Ricardo Azziz in Androgen

Excess Disorders in Women (2006), PCOS should not be diagnosed until other
hyperandrogenic disorders like Cushing's Disease have been ruled out. 1 Once other
possible disorders are excluded, clinicians can use one of two possible diagnostic criteria
to determine if a patient has PCOS. The first criteria was set by the National Institutes of
Health (NIH) in 1990 and defines PCOS as the presence of hyperandrogenemia and
chronic anovulation (the absence of ovulation), and the exclusion of other possible
disorders.1 The second criteria, called the Rotterdam Criteria, was developed in 2003 to
broaden the definition of PCOS to include additional phenotypes of the syndrome. The
Rotterdam Criterion defines PCOS as the presence of at least two out of three specific
symptoms: hyperandrogenism, menstrual dysfunction, and/or the presence of ovarian
cysts.1
Clinicians use a combination of techniques to determine whether patients have the
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characteristic symptoms of either the NIH or Rotterdam criteria. First, doctors may
observe phenotypical (visually observable) characteristics of PCOS in their patients.
These characteristics include hirsutism, masculine features, male-pattern balding, obesity,
and acne. 1.22 Second, doctors rely on patient reports of their symptoms. Patients may
report menstrual irregularities, infertility, unwanted hair growth on their face, chest, or
back, unwanted hair loss on their scalp, weight gain, or infertility. Doctors also use
clinical tests to confirm diagnosis. These tests include blood tests to determine hormone
levels, pelvic exams and ultrasound to determine if a patient has ovarian cysts, and
menstrual cycle tracking to diagnose menstrual irregularities and oligo- or
anovulation. i ,22
The NIH and Rotterdam criteria are both useful for the diagnosis of PCOS, but
approach diagnosis differently. The NIH criteria is most useful for diagnosing patients
who are at high risk of metabolic dysfunction, while the Rotterdam criteria is useful for
further defining phenotypes of PCOS where patients are more affected by reproductive
dysfunction.23 However, both the NIH and Rotterdam criteria are controversial. The NIH
criteria was developed through an informal poll of experts who diagnose and treat PCOS,
inquiring what the recognized features of the syndrome were.23 The NIH criteria
excluded polycystic ovaries because, despite its name, cysts are not always present in
patients with the other characteristic symptoms of PCOS.23 It was this exclusion that led
to the development of the Rotterdam criteria.23 However, rather than clarifying how to
diagnose PCOS, the Rotterdam criteria only served to demonstrate that there are multiple
types of PCOS. While this is useful knowledge to have, it has led to confusion in research
and clinical outcomes because the effects and complications of PCOS vary by
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phenotype.23 Most studies on PCOS do not constrain selection criteria to a single
phenotype, so it can be difficult to differentiate how the syndrome is affecting patients
differently, or how PCOS is responding differently to various treatments.

PCOS and Bone Density
Due to its extreme variability, PCOS is a difficult syndrome to understand and
much of the research available about its effect on BMD appear contradictory. Most
research suggests that certain symptoms of PCOS, such as hyperandrogenemia,
hyperinsulinemia (Insulin Resistance), and obesity, may positively affect bone growth
and mineral accumulation.3 For instance, weight gain and obesity may cause patients with
PCOS to have higher BMD in load-bearing regions of the skeleton, like the femoral head
or lumbar spine, since load-bearing bone density increases as weight increases. The
visceral fat associated with PCOS weight gain can cause excessive free androgen
production, which may be associated with increased BMD in non-load-bearing areas of
the skeleton. 16 However, existing research does not show whether the effect of PCOS
related obesity on bone density is a localized effect, increasing BMD only in specific
areas of the body, or a systemic one.
Contrary studies exist that suggest that patients with PCOS do not have higher
BMDs than healthy controls.2 This may be due to symptoms associated with PCOS that
have been shown to have a deleterious effect on BMD. Menstrual and ovulatory
dysfunction are significantly correlated to decreased BMD.24 Chronic vitamin D
deficiency, hypothyroidism, and hypoprogesteronemia (low progesterone) may
counteract any beneficial effect of PCOS on BMD.4• .25 Additionally, there is some
8

research that suggests that common treatments for PCOS, like insulin sensitizing agents
12

and androgen blockers, may reverse the beneficial effect of the symptoms those
medicines treat.2.3.26

Hyperandrogenemia
The primary concern of most researchers who study the skeletal effects of PCOS
is how hyperandrogenemia might cause patients with the syndrome to have different
BMD than healthy patients. Male and female sex hormones regulate the growth of bone,
accumulation of bone mineral, and signal epiphyseal plate fusion. 15•27 When these
hormones are imbalanced, bone development in both men and women becomes
abnonnal.27 It is possible that excessive androgen levels in patients with PCOS may
stimulate bone growth and mineralization at a faster or greater rate, causing patients with
PCOS to have a different body morphology than people without the syndrome. Indeed,
many do. A study in 2015 determined that lean patients with PCOS were more likely to
have a mesomorphic endomorph body type than healthy controls. 17 Mesomorphy refers to
one's muscle mass, while endomorph refers to one's body fat. 17 Other hormones, like
insulin, also affect how bone develops, and androgen seems to regulate how insulin is
received by bone tissue.27
High testosterone levels have also been linked to greater lean muscle mass in both
lean and obese patients with PCOS. In a study by Douchi and colleagues (2001), free
androgens associated with visceral fat increased lean muscle mass in arms, legs, and the
trunk, and that increased lean muscle mass was significantly associated with increased
regional BMD, regardless ofload-bearing. 13 However, the same study showed that serum
androgen levels were not associated with increased BMD. 13 A later study by the same
authors determined that patients with PCOS who are lean, or whose fat is distributed
13

more peripherally, did not have the same regionally increased BMDs as patients with
viscerally distributed fat. 16 It was detennined that the cause of this anomaly was that
peripheral fat does not produce free androgens the way visceral fat does, and the authors
detennined that this non-load-bearing effect of visceral fat was more significantly
associated with increased BMD than its load-bearing effects. 16

Menstrual and Ovulatory Dys/unction
According to a 1990 study by Davies, Hall, and Jacobs, there is a significant
correlation between amenorrhea and vertebral bone mineral density loss in
premenopausal women, except in women with PCOS.24 The authors of the study
hypothesize that the cause of bone mineral density loss in most cases of amenorrhea is
due to estrogen deficiency.24 This hypothesis is based on the purpose that estrogen serves
in bone growth and maintenance, which is to signal epiphyseal fusion, support the
retention of calcium in bone, and strengthen the bone matrix.15 However, amenorrhea in
patients with PCOS occurs without an estrogen deficiency because many women with the
syndrome have excessive estrogen secretion. 12 Individuals with a known history of
amenorrhea related to PCOS may not have vertebral bone density loss, or may have a
decreased rate of vertebral bone density loss than either healthy individuals or those with
amenorrhea unrelated to PCOS. Unfortunately, research comparing vertebral bone
mineral density of women with PCOS-related amenorrhea and healthy controls is lacking.

Insulin Resistance, Obesity, and Lean Muscle Mass
Another concern of researchers is the effect of hyperinsulinemia and obesity on
the skeletons of patients with PCOS. Insulin Resistance (IR} is a condition where the
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body's insulin receptors do not work properly, and this causes the body to overproduce
insulin, a state referred to as hyperinsulinemia.26 While IR is not considered a part of the
diagnostic criteria of PCOS, it is a symptom that is as common in patients with the
syndrome as hyperandrogenemia, and the importance of IR in diagnosing and treating
PCOS is well-recognized by researchers and clinicians.26
Obesity is also common in patients with PCOS, and while lean women may
develop the syndrome, obese and overweight body types are the most common.26
According to a study by Carmina and colleagues, PCOS was correlated with increased
lean muscle mass, and the factors most associated with increased lean muscle mass are
obesity and hyperinsulinemia.2 According to a meta study of research done on lean
muscle mass and femoral neck BMD by Ho-Pham and colleagues in 2013, lean muscle
mass is a statistically significant indicator of higher BMD in healthy men and women.28
Whether the associations between hyperinsulinemia, obesity, and increased lean muscle
mass correlate to higher BMD in patients with PCOS is not yet known. The meta-study
which suggests greater lean muscle mass correlates to greater BMD was conducted by
reviewing studies that looked at healthy individuals and focused on a load-bearing area of
the body. Given the difference between these populations and the population of patients
with PCOS, it is not possible to assume or infer that the results can be accurately applied
to the PCOS population. Carmina and colleagues (2009) found that the BMD of patients
with PCOS was similar to that of healthy controls.2 This contradicts the results of other
studies and suggests that hyperinsulinemia, obesity, and the resulting increased muscle
mass may not have a significant impact on BMD.2
It is also useful to note that insulin, like male and female sex hormones, is an
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important hormone for bone development, signaling bone tissue growth; mineralization,
remodeling, and epiphyseal plate fusion. 15 There are currently three recognized
phenotypes of IR which are characterized by defects of insulin receptors: autoimmune
disruption of insulin receptors (or the combination of hyperandrogenemia), IR, and
acanthosis nigricans (dark, thick patches of skin).29 Defects of insulin receptors and
autoimmune disruption of receptors are less common, but the third phenotype, called
HAIR-AN syndrome, affects 3% of patients with hyperandrogenic conditions, including
PCOS.29 It is possible that the hyperinsulinemic state caused by IR could heighten the
stimulation of bone mineralization to a degree that would explain the increased BMD
associated with PCOS. Hyperinsulinemia has also been shown to increase the production
of androgens in visceral fat, and may play a role in the correlation between
hyperandrogenemia and increased BMD. 1 6 Unfortunately, the effect of IR and
hyperinsulinemia on BMD is not well known because there is a lack of studies on this
possible avenue of skeletal change in PCOS. More research is needed to understand what
effect, if any, hyperinsulinemia and obesity have on the skeletons of patients with PCOS.

Comorbid Conditions with Possibly Deleterious Effect on BMD
At first glance, it would seem that the symptoms of PCOS create a net-benefit to
BMD, but there are specific comorbid conditions and treatment options that may have a
deleterious effect on bone mineralization. First, chronic and severe vitamin D deficiency
is common in patients with PCOS, and is associated with osteomalacia, which is a
demineralization in adult bone.8 There is little existing research on the incidence rate of
osteomalacia in PCOS patients, and it is not known whether chronic vitamin D deficiency
affects patients with PCOS in a similar fashion to the way it affects other patients.
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Secondly, a study by Armanini and colleagues (2013) found that many patients
with PCOS also had chronic, autoimmune thyroiditis (Ain with hypothyroidism.4 In that
study, 27% of patients with PCOS had AIT, with 47% of those patients having
subclinical hypothyroidism, compared to 8% of healthy controls.4 Autoimmune
hypothyroidism is caused by a deficiency in thyroxine, and both this deficiency and its
most common treatment, thyroxine replacement, have been indicated as risk factors of
bone density loss.4•5 AIT and hypothyroidism-associated BMD loss may occur through
thyroxine deficiency, while BMD loss associated with thyroxine replacement therapy
may be caused by thyroxine toxicity, though thyroxine toxicity is uncommon.4•5 The

n on BMD

existing research on the effect of thyroid hormone replacement therapy (HR

conflicts, but this may be due to the fact that thyroid HRT is heavily regulated to prevent
thyroxine toxicity.
In addition, a statistically significant difference in progesterone was observed
during the luteal phase (after ovulation and before menstruation) of the menstrual cycle in
patients with PCOS compared to healthy controls.25 It seems that the effect of low
progesterone in PCOS is primarily that it increases the risk factor of patients with PCOS
for pregnancy-related disorders and loss of pregnancy.25 However, because progesterone
plays a role in bone growth and development, like other sex hormones, low progesterone
levels may have an impact on BMD.25 However, very little research exists concerning the
possible effect of low progesterone and BMD in patients with PCOS.

Common Treatments and BMD
Treatment plans for PCOS are necessarily varied in response to the syndrome's
heterogeneous nature. Lifestyle changes and exercise are included in all treatment plans
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because these options have been shown to be useful across all phenotypes of PCOS.9 In
addition to lifestyle changes, patients with PCOS are commonly treated with one or more
of the following medications: androgen blocking medications, insulin sensitizing agents,
or hormonal birth control. These treatments may affect the way in which PCOS affects
BMD.
First, women with PCOS may be treated with exogenous sex hormones in the
form of oral, implantable, or injectable contraceptives. Hormonal oral contraceptives are
a common treatment for oligo- and amenorrhea in premenopausal women with PCOS.30
In women with oligo- or amenorrhea that is not associated with PCOS, these
contraceptives may prevent the BMD loss that is associated with menstrual and ovulatory
dysfunction.24 However, as mentioned earlier, patients with PCOS-related amenorrhea
have increased estrogen secretion, which may have a positive effect on BMD. This may
mean that any positive impact on B:MD associated with hormonal oral contraceptives is
absent, or that oral contraceptives do not have a similar effect in PCOS patients as the
effect observed in non-PCOS patients. The effect of implantable and injectable
contraceptives on bone density seems to be the subject of some debate among medical
professionals. In one study, depo medroxyprogesterone acetate injectable contraceptive
may have induced estrogen deficiency in the subjects studied, causing a statistically
significant decrease in bone density in those subjects compared to control subjects who
did not receive the injection.3 1 However, this study has been criticized for poorly
matching women in the test and control groups for other risk factors of low BMD like
cigarette smoking.32 Critics also pointed out that medroxyprogesterone has been shown to
be useful in the treatment of osteoporosis.32 Treatment of PCOS-associated oligo- and
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amenorrhea with injectable or implantable forms of contraceptives may have an effect on
the BMD of patients. However, little research has been done in this area, and conflicting
evidence of the effect of implantable and injectable contraceptives on BMD makes it
difficult to determine if these medications will induce estrogen deficiencies in patients
with PCOS to a degree that would have any effect on their BMD.
Secondly, insulin sensitizing medications like metformin hydrochloride are useful
in treating PCOS, making them a common addition to many patient treatment plans. The
medications are meant to staunch excessive insulin production as a response to Insulin
Resistance (IR), and mitigate the production of excessive male sex hormones and follicle
stimulating hormone.26 Therefore, insulin sensitizing agents may counteract the effect of
IR and hyperandrogenemia on bone growth and development. Similarly, androgen
suppression medications are used to prevent excessive secretion of male sex hormones,
and it is within the realm of possibility that these medications could lessen the effect of
hyperandrogenemia on BMD in patients with PCOS. Vitamin D supplementation, which
is used to resolve osteomalacia and other symptoms of vitamin D deficiency, may stop or
correct any demineralization that occurs in response to the chronic vitamin D deficiency
associated with PCOS. Finally, as mentioned in an earlier section, thyroid replacement
therapy to treat hypothyroidism may resolve any effect that hypothyroid conditions have
on BMD loss in patients with PCOS, or, in the event of over-medication, may cause
BMD loss.

Rationale
The literature about the skeletal effects of PCOS is incomplete, lacking in both
longitudinal studies, and those which compare full-body DEXA scans to more thoroughly
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correct for load-bearing bone density. Understanding PCOS and its impact on the
skeleton is crucial because it affects some 6.5-8.0% of the female population according to
projections made using the NIH Diagnostic Criterion.• This literature review highlights a
deficit of understanding of the effects of PCOS on BMD, a deficit that could be mended
through a study comparing the BMD of lean and obese patients with PCOS to that of
healthy controls. The goal of the current study is to determine whether there is a systemic
effect of PCOS on BMD and the direction of that effect. The secondary goal of the
present study is to determine whether the cranial vault is a useful region to study when
determining if changes to BMD in response to PCOS occur independently of mechanical
loading.
Further justification for a comparative study is that individuals with PCOS are
significantly more likely to suffer psychological distress than healthy women.33 One of
the reasons for this psychological stress is that patients with the disease feel they have
different, and unfeminine, bodies from healthy women.33 A more comprehensive picture
of how this syndrome impacts the lives of patients could help doctors better treat and
inform patients to increase their overall quality of life. Effective treatments like diet,
exercise, supplements, hormone therapies, and insulin sensitizing medications have been
shown to improve the quality of life of patients.33
Along with the burden on the physical and emotional well-being of patients, the
diagnosis and treatment of PCOS presents a massive economic burden on the healthcare
system. In 2006, the estimated cost of PCOS in the United States was $4.37 billion.34
Early detection of PCOS is a vitally important, cost effective way to reduce the economic
burden of the syndrome.34 However, early detection requires a more thorough
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understanding of the syndrome and its effects on the body. For these reasons, it is prudent
for researchers to bolster existing knowledge by creating studies that fill in gaps and more
rigorously attend to confounding issues.

Materials
This study was approved by the Eastern Michigan University Human Subjects
Review Committee, protocol number 896868-1. Subjects were required to confirm that
they were not pregnant before a DEXA scan could be completed. Over-the-counter
pregnancy tests purchased from a local pharmacy were used to ensure that no subjects
were pregnant. Female subjects were recruited from the Eastern Michigan University
student, faculty, and staff population, and from around Ypsilanti, Michigan. The selection
criteria for participation in the study included non-smoking, non-pregnant subjects aged
18 to 45 years who did or did not have PCOS. Subjects were separated into two groups
based on their health status. PCOS group subjects self-reported that they had been
diagnosed with PCOS and control group subjects self-reported that they had not been
diagnosed with PCOS. Study participants were recruited at EMU via email and posted
signs. Two subjects were recruited by word of mouth from other participants. The PCOS
group consisted of IO subjects with PCOS, and the control group consisted of 5 healthy,
age- and weight- matched subjects, none of whom were pregnant or at risk of being
pregnant.
The subject's height and weight were recorded for the purposes of finding age and
weight matched controls. Subjects were also given a given a full-body dual-energy x-ray
absorptiometry (DEXA) scan to measure total body BMD, as described below. The
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scanner was operated by a trained member of the investigative team, thesis advisor Dr.
Megan Moore. The DEXA device used was a GE Healthcare Lunar Prodigy Pro housed
in the Eastern Michigan University Office of Nutrition Services. Printouts of each body
composition scan provided the data for this study, and statistical analysis of the data was
completed using IBM SPSS™ Statistics 21.0 and Microsoft Excel™.

Methods
At the beginning of each scanning session, the study protocol was explained and
informed consent was obtained via a consent form that explained the purpose,
procedures, requirements, and details of the study, including any risks and policies in
place to mitigate risk. Subjects were then escorted to a restroom and provided an over
the-counter pregnancy test. Pregnancy tests were self-administered, and one of the
investigators verified the results of each test. Pregnancy waiver forms stating that the
subject was not pregnant were signed by each subject after a negative pregnancy test
result was obtained, and signed by the investigator, who acted as witness to the test result.
Subjects were then assigned a numerical code to ensure anonymity of their data. A health
status questionnaire was administered to determine if the subjects had conditions known
to be comorbid with PCOS and to record whether they were taking any medicines to treat
PCOS, insulin, or if they used hormonal implantable or hormonal injectable
contraceptives, which are known to affect BMD (Appendix A). Subjects were then asked
to weigh themselves so that the DEXA device could be calibrated for their body size.
Once these steps were completed, subjects were asked to remove their shoes, and all
metal jewelry or clothing with metal components. Subjects were then asked to lie still on
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the DEXA device, and an investigator ensured that the subject was positioned correctly.
The subject's legs were strapped together to prevent movement, and participants were
asked not to speak until an investigator cleared them to do so to minimize movement of
the chest and arms. Once subjects were properly positioned and still, a total body bone
mineral density scan was performed according the GE Healthcare Lunar Prodigy Pro
device manufacturer's guidelines. If one of the subjects' arms and/or legs did not fit on
the scanning table, the DEXA scanner automatically estimated the BMD and body
composition from the opposite side of the body. The DEXA device was operated by a
trained member of the investigative team, thesis advisor Dr. Megan Moore. There were
no adverse events reported during this research.
Subject's BMI and BMDTotaJ were calculated during the initial scan and no region
of interest was selected to obtain these data. After each initial scan, subjects were
provided with a printed report of their scan data, along with a pre-printed informational
sheet explaining the results of their scan. In addition, Dr. Megan Moore explained the
results of the scan to each subject. A second copy of each subject's initial report was
printed for use by the investigative team. The default region of interest selected
automatically for the head (BMDHcad) was used initially, saved, and printed. The region
of interest for the head was then manually moved so that the box around the vault started
just above the teeth and that the total volume of the cranial vault (BMD vau11) was set to
between 1 18 cc and 121 cc. The results were saved and printed a third time.

Statistical Analysis
Data obtained at scanning sessions was entered into a spreadsheet format for use
with IBM SPSS™ Statistics 2 1.0 software. Partial correlations were used to assess
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correlations between BMI and BMOrotal, BMDHead, and BMDvault controlling for age.
These tests were completed for the total, control, and PCOS samples. Nonparametric
correlations using Kendall's tau coefficient were used to compare Age and BMDro1a1,
BMDHead, and BMDvault for each sample. Finally, nonparametric correlations using
Kendall's tau coefficient were used to compare BMDvault and BMOrotal for each sample.
Partial correlations were used to determine the strength and direction of the linear
relationship between BMI and BMDro1a1, BMDttead, and BMDvault. As a person ages,
BMD should change, so it was necessary to set Age as the covariate (control variable) to
see how BMI correlated to BMD independently from the effect of subject's ages.
Nonparametric correlations, specifically Kendall's tau, were performed because the
sample size was too small to assume normal distribution. Kendall's tau is comparable to
other nonparametric statistical models, such as Spearman's R, in terms of statistical
power, but differs in magnitude and interpretation.35

Results
The average age of subjects was 29.5 years in the total sample, 27.3 years in the
control sample, and 30.6 years in the PCOS sample (Table 1). The average BMI of the
subjects was 35.6 kg/m2 in the total sample, 29.8 kg/m2 in the control sample, and 38.4
kg/m2 in the PCOS sample (Table 1). The average BMDrota1 ofsubjects was 1.280 g/cm2
(SD = 0.071) in the total sample, 1.236 g/cm2 (SD = 0.078) in the control sample, and

1.303 g/cm2 (SD = 0.060) in the PCOS sample.
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Table 1. Demographic data for Total, Control, and PCOS Samples

N

Mean Age

Mean BMI

Total Sample

15

29.5

35.6

Control Sample

5

27.3

29.8

PCOS Sampl�

10

30.6

38.4

A significant correlation between BMDHcad and Age was observed in the PCOS
sample (r = 0.644; p = 0.009), and the total sample (r = 0.383;p = 0.047) (Table 2).
However, while the correlation between BMDvault and Age was significant in the PCOS
sample (r = 0.556; p = 0.025), it was not significant in the total sample (Table 2).
Correlations between BMDro1111 and Age were not significant in either the total or PCOS
sample (Table 2). However, the correlation ofBMDrota1 and Age in the PCOS sample
was stronger than the correlation observed in the control sample (r 0.200; p = 0.624).
g

Table 2. Nonparametric correlations between Age and BMDTollll, BMDHcad, and BMDvault
BMDTollll

BMDHcad

BMDvaull

:fotal Sample Age

0.329
(0.091)

0.383
(0.047)*

0.356
(0.066)

PCOS Sample Age

0.405
(0.106)

0.644**
(0.009)

0.556*
(0.025)

P-values shown in parentheses
• Correlation is significant at the 0.05 level (2-tailed).
•• Correlation is significant at the 0.01 level (2-tailed).

Additionally, significant correlations existed between BMDTolal and BMDvault in
the total sample (r = 0.386; p = 0.047) and the control sample (r = 0.800; p = 0.050), but
no significant correlation was observed in the PCOS sample (r = 0.135; p = 0.590) (Table
3). Furthermore, no significant correlation between BMDvault and BMDTolal controlling
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for age was observed in the PCOS sample (fable 4}.
Table 3. Nonparametric correlations between BMD vault, and BMDi-otat
BMDTotel
BMil>vauit
Total Sample

0.386•
(0. 041}

BMDvault
Control Sample

0.800*
(0.050)

BMF>vauit
PC0S SafQple

0.13 5
(0.590�

P-values shown in parentheses
• Correlation is significant at the 0.05 level (2-tailed).

Table 4. Partial correlations ofBMD vault and BMDi-otat controlling age in PCOS sample

I

BMil>vau1t
1RC@S �le

.,;QJ.43
(0.11.4)

P-values shown in parentheses

The significant correlation between BMD vault and Age in PCOS is a positive
correlation, meaning that BMD vault increased with Age in the PCOS sample (Figure I}.
The correlation ofBMDTotal and BMD vnult in the control sample is strongly positive
(Figure 2}, but this is not so in the PCOS sample (Figure 3). A slightly stronger positive
correlation between BMDTotat and Age was observed in the PCOS sample (r = 0.405; p =
0.106} (Figure 4} than in the control sample (r = 0.200; p = 0.624}. However, neither of
these correlations is statistically significant (p = 0.050}.
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PCOS Sample
0

3--'0D

0

2

UOO
18.D

23.0

310

38.Q

33.0

43.0

Age

Figure 1. Correlation ofBMDvault and Age in the PCOS Sample (r = 0.556)

Control Sam le

0

0
t� 1 .250
ID

1 ,\50

1.800

2.800

BMD Vault

Figure 2. Correlation of BMDrota1 and BMDvoult in the Control Sample (r ,;;;, 0.800)
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PCOS Sample
1.1100
0

0
1.350

2.300

1 .800

2.900

BMD Vault

Figure 3. Correlation ofBMDTotal and BMDvault in the PCOS Sample (r = 0.135)
PCOS Sample
1

;; 1
�
l-

o
:.:
m ,

18.0

2:1 0

:211.0

33.0
Age

31.Q

43.0

Figure 4. Correlation between BMDTotal and Age in the PCOS Sample (r = 0.405)
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Discussion
The first purpose of the present study is to determine whether PCOS has an effect
on BMD. While much of the existing research on this topic suggests a significant positive
correlation between PCOS and BMD, other research suggests no correlation exists. This
study found a positive relationship between BMDrota1 and Age in both the PCOS and
control samples, but neither relationship was statistically significant. However, the
relationship between BMDr0ta1 and Age in the PCOS sample (r = 0.405) was slightly
stronger than the relationship between BMDTotal and Age in the control sample (r =
0.200). These results are similar to the results of existing research; increased BMD is
observed in subjects with PCOS, but this increase is not significantly different than what
is observed in healthy subjects.
The second goal of the present study was to determine if any effect of PCOS
observed is systemic. The results of this study show a significant positive correlation
between BMDv11u1t and Age in the PCOS sample, which is not observed in the control
sample. Additionally, the BMDvault of PCOS subjects is increasing independently of
BMI. These results suggest that PCOS has a meaningful, systemic effect on BMD that is
not occurring in healthy control subjects. Further evidence for a systemic effect on BMD
is observed when the correlations between BM0v11u1t and BMDrota1 of each sample are
compared. In the control sample, this correlation is significant (p = 0.050), meaning that
BM0v11u1t is changing in tandem with BMDTotaI. The correlation between BMDvault and
BMDTotal in the PCOS sample is not significant, suggesting that BM0vau11 is changing
independently of BMDTotaJ.
The final purpose of this research is to determine whether the cranial vault region
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of the skeleton is a useful region to study to understand what impact PCOS has on BMD.
As mentioned above, no significant correlation

between BMDvault and BMDTotat was

found in the PCOS sample despite a significant correlation between BMDvautt and Age.
These results support the conclusion that PCOS has a systemic effect on BMD, because
there is not a significant correlation between BMDvault and BMDTotat, like the one
observed in the control sample. These results also support the conclusion that BMDvault is
a useful region to study when trying to determine the effect of PCOS on the skeleton.
These conclusions illustrate how research that focuses on load-bearing regions of the
skeleton may not be providing a complete view of how PCOS is affecting the skeleton.
Results that show a slight increase in BMDT01a1 were expected by the investigators
of the present study, given the results of previous research studying the effect of PCOS
on BMD. Male and female sex hormones play a similar role in supporting the retention of
calcium in bone and strengthening bone matrix. 15 Additionally, one of the primary
symptoms of PCOS is excessive secretion of androgens, often presenting as hirsutism,
which is positively correlated with increased bone density in women with
oligomenorrhea or amenorrhea, likely due to the effect of androgens on bone growth and
calcium retention. 1 • 15.27 Most research on the effect of PCOS on BMD suggests that the
high levels of androgens and follicle stimulating hormones present in women with PCOS
have a positive effect on BMD, both by influencing bone growth and development, and
possibly preventing bone mineral density loss. This hypothesis is supported by the
current study because the BMDvault (unaffected by mechanical loading) increased with
age in the PCOS sample. The opposite is expected in healthy females, in which bone
mineral density decreases with age.36
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The lack of significant difference between the correlation of BMDTotaJ and Age in
the PCOS and control samples is also expected, because many comorbid conditions of
PCOS are linked to lower BMD, and many of its treatments may ameliorate the positive
effect of high male sex hormones and hirsutism. For instance, Autoimmune Thyroiditis is
a commonly comorbid condition with PCOS, and both this disorder and its most common
treatment have been linked to BMD loss.4•5 Additionally, common treatments for PCOS
like insulin sensitizing agents and androgen suppressants mitigate symptoms of PCOS
that researchers theorize may be the source of the effect of PCOS on BMD, like helping
patients lose visceral weight that causes excessive free testosterone secretion. 1 6•26 It is
important to consider that while neither the correlation of BMDTotaJ and Age in the PCOS
sample or the control sample are significant, the relationship between BMDT01111 and Age
is slightly stronger in the PCOS sample, suggesting that the syndrome does have an effect
on BMD.
The investigators also expected to confirm that the cranial vault region is a truly
non-load-bearing region of the skeleton, as existing research on the usefulness of the
cranial vault region exists.37 A study by Turner et. al. (1997) determined that the cranial
vault region is not affected by mechanical loading from body weight or activity, and that
assessing BMD using the cranial vault can be useful for determining how patients are
responding to treatment.37 The present study takes this information a step further,
suggesting that cranial vault BMD is useful for assessing the systemic effect of disease on
BMD.
However, unexpected results were obtained by this study. First, it was surprising
to see a strong, positive correlation in BMDvault and Age in the PCOS sample. This result
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is the opposite of what was observed in the control sample, and contrary to existing
research which suggests that BMD decreases with age.36 Also, the lack of correlation
between BMDvault and BMDTota1 when controlling for age in the PCOS sample is
unexpected. In the PCOS sample, BMDv11ult is changing independently of BMDr01a1, but
this conflicts with general knowledge about BMD. BMDvault should increase or decrease
in tandem to increases or decreases in BMDTotal, as illustrated by the strong correlation
between the two in the control sample. The unexpected results obtained by this study
raise important questions about the role of PCOS in women's bone health, suggesting
additional research is needed to understand the complex effect of PCOS on BMD.

Limitations of this Study
There are issues with this study that need to be addressed in an expanded study.
First, subjects self-reported their health status, and it was not possible to confirm these
diagnoses, or determine free testosterone or serum hormone levels. Therefore, this study
cannot determine if the effect of PCOS on BMD observed is equally applicable to all
subphenotypes of PCOS. It may not be possible, with the current lack of data on how
PCOS manifests and affects the health status of patients suffering from the various
phenotypes, to develop a study that could sufficiently delineate between the phenotypes.
This is a known issue in PCOS research. Furthermore, it is not possible to determine what
factors of PCOS may be causing the syndrome to affect systemic BMD without
confirming such things as serum hormone levels and free testosterone levels, and
comparing lean muscle mass of PCOS subjects and healthy controls. However, this study
is not designed to pinpoint the cause of the effect of PCOS on BMD. The investigators
sought only to determine whether PCOS has an effect on BMD, if the effect of PCOS is
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systemic or localized, and whether BMDvault is a sufficient metric of the effect of PCOS
on BMD.
Secondly, the sample size (N = 15) of this study is small and the selection region
is primarily constrained to the Eastern Michigan University campus population. The
results of this pilot study are not meant for population-level analysis. Rather, the study
was intended to provide justification for an expanded study with a larger sample size.
Finally, the eligibility criteria of this study were too broad. The criteria did not
exclude or delineate nonparous subjects from those who had been pregnant and had given
birth. Pregnancy can have a negative effect on a person's BMD if the pregnant person
does not increase calcium intake to mitigate this effect. Secondly, the broad eligibility
criteria made it difficult to match participant's weight. A I -tailed Mann-Whitney test
showed a significant difference (p = 0.049) between the BMI of the PCOS sample and
control sample. Also, as mentioned above, the eligibility criteria did not restrict subjects
to one subphenotype of PCOS, or allow the investigators to group PCOS subjects by
subphenotype.

Future Research
Multiple avenues of further research are recommended for this topic. This study is
a pilot study, and an expanded study with a larger sample size is needed to both confirm
the results and apply this research to population-level generalizations. Such a study is
justifiable given the results of this study, and could be developed to account for the issues
mentioned in the previous section. Additionally, further research could be done to
determine whether PCOS has a protective effect on BMD during and after menopause,
and if patients with PCOS are at lower risk of fracture than healthy controls. Research
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has been conducted to study the effect of PCOS on BMD during menopause that shows
strong, positive correlations between serum sex hormone levels and BMD.38 A long-term
study by Brannstrom and colleagues (2012) also found a significant positive correlation
between PCOS and higher sex hormones during and after menopause, but suggests that
peri- and postmenopausal patients with PCOS have a similar fracture risk compared to
healthy controls.38 Another study suggests that male sex hormones have a differential
effect on types of bone in postmenopausal women, and further research could be initiated
to determine how various hyperandrogenic conditions like PCOS influence types of
bone.39
Other avenues of research include studying the effect of PCOS on BMD in
patients who have had children, or whether pregnant patients with PCOS are able to
absorb calcium more easily than healthy controls. It is also possible that patients with
PCOS reach peak bone mass at a later age than healthy controls, or that bone growth and
development in patients with PCOS differs in some other, relevant way to healthy
controls. Another avenue ofresearch is determining which symptoms of PCOS affect
BMD, and to what degree. For instance, while this study shows a systemic effect of
PCOS on BMD that is unrelated to mechanical loading, the increased BMis and lean
muscle mass associated with PCOS may have specific effects on BMD in load-bearing
areas of the skeleton.

Conclusion
PCOS is a complex syndrome affecting an estimated 6.5 to 8.0% ofwomen.1
Despite its considerable incidence rate, the cause of PCOS is not known, and little is

34

understood about the immediate or long term impact of the syndrome. Clinically, patients
with PCOS present with a wide array of symptoms and comorbid conditions of a varying
severity, and the syndrome changes as women age. For these reasons, PCOS is
considered by many doctors and researchers to be a serious public health concern.
Despite the difficulties in studying PCOS, it is important for clinicians and researchers to
study the syndrome closely and add to the general knowledge and understanding of the
disease. As general knowledge of PCOS increases, the real scope of the syndrome can be
determined. Additionally, new methods of managing the disease will emerge in response
to a better understanding of PCOS, leading to better clinical outcomes for patients, and
de-stigmatization of the disease among medical professionals and the general populace.
One area in which information about the effect of PCOS is scarce is how the
syndrome affects BMD. PCOS is characterized by symptoms which may increase BMD,
like hyperandrogenemia, insulin resistance, and obesity. However, little is understood
about the lasting effects of PCOS, and the syndrome includes common secondary
symptoms and comorbid conditions which may reduce BMD, like chronic vitamin D
deficiency, and Hashimoto's Thyroiditis. The literature reviewed in this paper suggests
that a correlation between PCOS and BMD does exist, but this literature focuses on load
bearing areas of the skeleton when measuring BMD. Such studies may not adequately
illustrate whether the effect of PCOS is systemic or localized because patients with PCOS
are likely to have overweight or obese BMis, and significantly more likely to have
increased lean muscle mass. These symptoms of PCOS will increase BMD in load
bearing areas of the body, which are naturally denser to accommodate a person's weight.
With these issues in mind, the current pilot study was developed. The goals of this
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study were to determine if PCOS has an effect on BMD, if the effect is systemic, and to
provide additional justification for the use of the cranial vault BMD as an appropriate
metric for clarifying the first two points. The results of this study suggest that BMDvautt
increases with age in patients with PCOS, though the opposite result is found in healthy
controls. Additionally, this study found that BMDvault does not correlate with BMDTotnl,
and that BMDTotaJ does not correlate with BMI in PCOS subjects. However, in control
subjects, BMDTotnl was significantly correlated to BMI. These results suggests that the
effect of PCOS on BMD is systemic, and that BMI affects BMDTo!lll differently in
patients with PCOS than in healthy controls. Finally, the present study determined that
the effect of PCOS on BMDvault is independent of mechanical loading, providing
justification for using the cranial vault BMD as a region for determining whether the
effect of PCOS on BMD is systemic.
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Appendix A
Health Status Questionnaire

Please answer the questions below as accurately as you are able. You will be able to
verify your answers again before you leave your session.
l . Have you been diagnosed with Polycystic Ovarian Syndrome (PCOS)?
D YES

O NO

D NOT SURE

2. Have you been diagnosed with hypothyroidism, such as Hashimoto's Thyroiditis?
D YES

O NO

O NOT SURE

3. Have you been diagnosed with a vitamin D deficiency?
D YES

O NO

O NOT SURE

4. Have you been diagnosed with Type I or Type II Diabetes?
D YES

O NO

D NOT SURE

5. Have you been diagnosed with Insulin Resistance or hyperinsulinemia?
D YES

O NO

D NOT SURE

6. Do you take any of the following medications?
Metformin HCl:
(Other names: Glucophage, Glucophage XR,
Glumetza, Fortamet, Riomet)

D YES O NO

Insulin:

D YES O NO

Hormonal Injectable Contraceptive:
(Depot medroxyprogesterone acetate, Depo
Provera)

D YES O NO

Hormonal Implantable Contraceptives:
(Other names: Nexplanon, Implanon)

D YES O NO

7. If you use hormonal contraceptives, please write the name of the medication
below:

By completing this questionnaire, you certify that the answers provided are true and
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accurate to the best of your knowledge.
To be completed by the investigator:

CODE: _________
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